Literature DB >> 10487907

Nerve conduction impairment in experimental diabetes-proximodistal gradient of severity.

J Patel1, D R Tomlinson.   

Abstract

We compared a conventional method of measurement of sciatic motor and sensory nerve conduction velocity, with a novel procedure that measures conduction in an 8-mm segment of the rat sural nerve. Conventional procedures gave reductions in velocity of 20% and 14% for motor and sensory fibers, respectively, whereas sural sensory fibers showed a 40% reduction (P <0.05). Changes were attenuated by treatment with either an aldose reductase inhibitor or a gamma-linolenic acid-alpha-lipoic acid conjugate, such that values from conventional procedures were not significantly different from controls and the sural sensory deficit halved. Putative motor fibers of the sural nerve showed no conduction velocity deficit in diabetic rats. Measurement of chronaxie and rheobase in sural sensory fibers revealed mild reductions in excitability in diabetics, with prevention of the chronaxie change by the treatments. Thus, measurement of sensory conduction in distal nerve segments show more profound defects in diabetic rats and may give a truer picture of preventive drug efficacy. Copyright 1999 John Wiley & Sons, Inc.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10487907     DOI: 10.1002/(sici)1097-4598(199910)22:10<1403::aid-mus10>3.0.co;2-z

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  2 in total

1.  Vincristine-induced neuropathy in rat: electrophysiological and histological study.

Authors:  Feras M H Ja'afer; Farqad B Hamdan; Faiq H Mohammed
Journal:  Exp Brain Res       Date:  2006-05-31       Impact factor: 1.972

2.  Phosphorylation of c-Jun N-terminal kinase (JNK) in sensory neurones of diabetic rats, with possible effects on nerve conduction and neuropathic pain: prevention with an aldose reductase inhibitor.

Authors:  A B Middlemas; S Agthong; D R Tomlinson
Journal:  Diabetologia       Date:  2006-02-03       Impact factor: 10.122

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.